Physicians' Education Resource
VerifiedJournal
Physicians' Education Resource®, LLC (PER®) is dedicated to advancing cancer care through professional education.
Accredited by the Accreditation Council for Continuing Medical Education (ACCME) and approved as a nursing continuing education provider by the California Board of Registered Nursing (CBRN), PER® is the educational resource of choice for live and online activities focusing on oncology and hematology. Based on identified needs and practice gaps, PER® provides high-quality, evidence based activities featuring leading national and international faculty with a focus on practice changing advances and standards of care in treatment and disease management. Activities may also include topics on emerging strategies currently under investigation, supportive care, diagnosis and staging, prevention, screening and early detection, and practice management. Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Accepts contributed content | Yes |
Recent Articles
Search ArticlesTumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology
Activity Overview This educational activity is an archive of the live presentation held on May 31, 2026. For more information about this educational activity, the faculty, and disclosures, please click here.
ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
Assistant Professor of Clinical Medicine University of California, Los Angeles Los Angeles, CA Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BristolMyers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, GSK, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Nuvation Bio, Oncocyte, Pfizer, Regeneron, Sanofi, Whitehawk Therapeutics;...
Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer
Program InfoFacultyDisclosures/Disclaimers Activity Overview Hormone receptor–positive/HER2–negative (HR+/HER2–) metastatic breast cancer remains one of the most common and challenging diagnoses in oncology. While CDK4/6 inhibitor-based therapy has transformed first-line treatment, management of disease progression continues to evolve rapidly with the emergence of next-generation oral selective estrogen receptor degraders (SERDs) and targeted combination strategies.
Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations
Professor of Medicine Weill Cornell Medical College at Cornell University Attending Physician Memorial Sloan Kettering Cancer Center New York, NY Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Alligator Bioscience, AstraZeneca, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene Therapeutics, Novartis, Servier, Tango Therapeutics, Tempus, Vector Pharma,...
Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us
Program InfoFacultyDisclosures/Disclaimers Activity Overview This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– breast cancer. In this educational program, these experts discuss the evolving treatment landscape for HR+/HER2– breast cancer. The program features dynamic discussions, practical insights, and updates from pivotal clinical trials that provide actionable guidance for optimizing patient care.
Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia
Overview: The management of polycythemia vera (PV) and essential thrombocythemia (ET) is improving with the development of novel therapies that raise new questions about optimal treatment sequencing, patient selection, and long-term disease management. This live, virtual webcast brings together expert faculty to address key challenges in the management of PV and ET through integrating real-world patient cases with concise data presentations and structured panel discussions.
A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes
This educational activity is directed toward medical/hematologists oncologists, hematologists, advanced practice providers, nurses, and other HCPs involved in the management of hematologic malignancies.
Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us
Accreditation/Credit Designation Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hematologic Malignancies
Flights United Airlines is pleased to offer discounts for 10th Annual Live Medical Crossfire®: Hematologic Malignancies attendees. To make flight reservations online please click on the discount code below: ZSHP544745 MileagePlus® members earn miles for their travel when using the United Meetings℠ discount code.
Show Me the Data®: From Mutation to Action — KRAS as a Therapeutic Target in PDAC
Activity Overview This online, on-demand virtual symposium brings together renowned experts in advanced pancreatic ductal adenocarcinoma (PDAC). In this educational program, these experts discuss emerging approaches to target KRAS in advanced PDAC, framed in the discussion of challenging case scenarios where novel treatments could fit. This educational activity is an archive of the live symposium held on April 11, 2026.